AVLAYAH is an enzyme replacement therapy that is indicated for pediatric patients weighing at least 5 kg who are either presymptomatic or symptomatic prior to advanced neurologic impairment. The approval was based on a Phase 1/2 clinical trial that demonstrated a 91% reduction in cerebrospinal fluid heparan sulfate levels, a key disease biomarker, by week 24 of treatment. The trial results indicated that 93% of patients treated with AVLAYAH had heparan sulfate levels within the normal range, showcasing the drug's potential effectiveness.
Ryan Watts, Ph.D., CEO of Denali Therapeutics, emphasized the significance of this approval for the Hunter syndrome community, stating, "The approval of AVLAYAH is a new era for the Hunter syndrome community as we deliver the first FDA-approved therapy designed to cross the brain's protective barrier for individuals and families living with this debilitating disease."
The FDA's decision also included the awarding of a Rare Pediatric Disease Priority Review Voucher (PRV) to Denali, which can be used to expedite the review process for future marketing applications. Denali plans to conduct further studies, including the ongoing Phase 2/3 COMPASS study, to confirm the clinical benefits of AVLAYAH across the patient spectrum.
This approval not only highlights Denali's innovative TransportVehicle™ platform, which enables the delivery of biologics to the brain, but also sets a new standard of care for treating neurologic manifestations of Hunter syndrome, a condition that has long posed significant challenges for patients and healthcare providers alike.
